Stock Track | Guardant Health Soars 5.66% After-Hours on Q2 Earnings Beat and Raised Guidance

Stock Track

Jul 31, 2025

Guardant Health Inc. (NASDAQ: GH) saw its stock surge 5.66% in after-hours trading on Wednesday following the release of its second-quarter 2025 financial results, which surpassed analyst expectations. The precision medicine company, focused on improving cancer care, not only reported strong quarterly performance but also raised its full-year revenue guidance.

For Q2 2025, Guardant Health reported revenue of $232.10 million, representing a 31% increase year-over-year and beating the consensus estimate of $211.20 million. The company's adjusted earnings per share (EPS) came in at -$0.44, significantly better than the expected -$0.79. Additionally, adjusted EBITDA was -$51.90 million, outperforming the estimated -$58.10 million.

The strong performance was driven by several factors, including a 30% increase in oncology test volume and improved reimbursement rates. The company also noted strong demand for its Shield tests, contributing to revenue growth in the screening segment. Based on these positive results, Guardant Health raised its 2025 revenue guidance to $915-$925 million. The company now expects oncology revenue to grow 20% year-over-year, with screening revenue projected at $55-$60 million for the year. The biopharma and data segment is anticipated to see growth in the mid-teens for 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1163880919"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163880919\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163880919?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 04:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163880919","market":"nz","top_or_hot":-1,"title":"Stock Track | Guardant Health Soars 5.66% After-Hours on Q2 Earnings Beat and Raised Guidance","media":"Stock Track","content":"<p>Guardant Health Inc. (NASDAQ: GH) saw its stock surge 5.66% in after-hours trading on Wednesday following the release of its second-quarter 2025 financial results, which surpassed analyst expectations. The precision medicine company, focused on improving cancer care, not only reported strong quarterly performance but also raised its full-year revenue guidance.</p>\n\n<p>For Q2 2025, Guardant Health reported revenue of $232.10 million, representing a 31% increase year-over-year and beating the consensus estimate of $211.20 million. The company's adjusted earnings per share (EPS) came in at -$0.44, significantly better than the expected -$0.79. Additionally, adjusted EBITDA was -$51.90 million, outperforming the estimated -$58.10 million.</p>\n\n<p>The strong performance was driven by several factors, including a 30% increase in oncology test volume and improved reimbursement rates. The company also noted strong demand for its Shield tests, contributing to revenue growth in the screening segment. Based on these positive results, Guardant Health raised its 2025 revenue guidance to $915-$925 million. The company now expects oncology revenue to grow 20% year-over-year, with screening revenue projected at $55-$60 million for the year. The biopharma and data segment is anticipated to see growth in the mid-teens for 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Guardant Health Soars 5.66% After-Hours on Q2 Earnings Beat and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Guardant Health Soars 5.66% After-Hours on Q2 Earnings Beat and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-07-31 04:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guardant Health Inc. (NASDAQ: GH) saw its stock surge 5.66% in after-hours trading on Wednesday following the release of its second-quarter 2025 financial results, which surpassed analyst expectations. The precision medicine company, focused on improving cancer care, not only reported strong quarterly performance but also raised its full-year revenue guidance.</p>\n\n<p>For Q2 2025, Guardant Health reported revenue of $232.10 million, representing a 31% increase year-over-year and beating the consensus estimate of $211.20 million. The company's adjusted earnings per share (EPS) came in at -$0.44, significantly better than the expected -$0.79. Additionally, adjusted EBITDA was -$51.90 million, outperforming the estimated -$58.10 million.</p>\n\n<p>The strong performance was driven by several factors, including a 30% increase in oncology test volume and improved reimbursement rates. The company also noted strong demand for its Shield tests, contributing to revenue growth in the screening segment. Based on these positive results, Guardant Health raised its 2025 revenue guidance to $915-$925 million. The company now expects oncology revenue to grow 20% year-over-year, with screening revenue projected at $55-$60 million for the year. The biopharma and data segment is anticipated to see growth in the mid-teens for 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1163880919","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163880919","pubTimestamp":1753907824,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Guardant Health Inc. (NASDAQ: GH) saw its stock surge 5.66% in after-hours trading on Wednesday following the release of its second-quarter 2025 financial results, which surpassed analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"个股追踪|Guardant Health盘后飙升5.66%，因Q2盈利超出预期并上调指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"Guardant Health Inc. (NASDAQ: GH) saw its stock surge 5.66% in after-hours trading on Wednesday following the release of its second-quarter 2025 financial results, which surpassed analyst expectations. The precision medicine company, focused on improving cancer care, not only reported strong quarterly performance but also raised its full-year revenue guidance.\nFor Q2 2025, Guardant Health reported revenue of $232.10 million, representing a 31% increase year-over-year and beating the consensus estimate of $211.20 million. The company's adjusted earnings per share (EPS) came in at -$0.44, significantly better than the expected -$0.79. Additionally, adjusted EBITDA was -$51.90 million, outperforming the estimated -$58.10 million.\nThe strong performance was driven by several factors, including a 30% increase in oncology test volume and improved reimbursement rates. The company also noted strong demand for its Shield tests, contributing to revenue growth in the screening segment. Based on these positive results, Guardant Health raised its 2025 revenue guidance to $915-$925 million. The company now expects oncology revenue to grow 20% year-over-year, with screening revenue projected at $55-$60 million for the year. The biopharma and data segment is anticipated to see growth in the mid-teens for 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}